DE4138042A1 - EPOTHILONES, THEIR PRODUCTION PROCESS AND MEANS CONTAINING THEM - Google Patents

EPOTHILONES, THEIR PRODUCTION PROCESS AND MEANS CONTAINING THEM

Info

Publication number
DE4138042A1
DE4138042A1 DE19914138042 DE4138042A DE4138042A1 DE 4138042 A1 DE4138042 A1 DE 4138042A1 DE 19914138042 DE19914138042 DE 19914138042 DE 4138042 A DE4138042 A DE 4138042A DE 4138042 A1 DE4138042 A1 DE 4138042A1
Authority
DE
Germany
Prior art keywords
epothilones
methanol
merck
epothilone
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19914138042
Other languages
German (de)
Other versions
DE4138042C2 (en
Inventor
Gerhard Prof Dr Hoefle
Norbert Dr Bedorf
Klaus Dr Gerth
Hans Prof Dr Reichenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GESELLSCHAFT fur BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 3300 BRAUNSCHWEIG DE
Original Assignee
GESELLSCHAFT fur BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 3300 BRAUNSCHWEIG DE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GESELLSCHAFT fur BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 3300 BRAUNSCHWEIG DE filed Critical GESELLSCHAFT fur BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 3300 BRAUNSCHWEIG DE
Priority to DE19914138042 priority Critical patent/DE4138042C2/en
Priority to AU29437/92A priority patent/AU2943792A/en
Priority to PCT/EP1992/002656 priority patent/WO1993010121A1/en
Publication of DE4138042A1 publication Critical patent/DE4138042A1/en
Application granted granted Critical
Publication of DE4138042C2 publication Critical patent/DE4138042C2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Abstract

Epothilones having general formula (I), a process for preparing the same and epothilone-containing agents are disclosed.

Description

Die Erfindung betrifft Epothilone der folgenden allgemeinen Formel:The invention relates to epothilones of the following general formula:

worin R¹ Wasserstoff, C₁-C₄-Alkyl, C₁-C₄-Acyl, Li⁺, K⁺, Na⁺, 1/2 Mg2+ oder 1/2 Ca2+ bedeutet und R² Wasserstoff oder eine Methylgruppe darstellt.wherein R¹ is hydrogen, C₁-C₄-alkyl, C₁-C₄-acyl, Li⁺, K⁺, Na⁺, 1/2 Mg 2+ or 1/2 Ca 2+ and R² represents hydrogen or a methyl group.

Ferner betrifft die Erfindung eine Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: The invention further relates to an epothilone, characterized by one or more of the following parameters:  

C₂₆H₃₉NO₆S[493]
FAB-MS (neg. Ionen): 429.25 für (M-H)-
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)C₂₆H₃₉NO₆S [493]
FAB-MS (neg. Ions): 429.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)

IR Film auf Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1 IR film on Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1

DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 1
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzen auf 120°C, braune AnfärbungDC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90: 1
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown color

HPLC: Rt = 5,4 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nmHPLC: R t = 5.4 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm

Des weiteren betrifft die Erfindung ein Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: The invention further relates to an epothilone, characterized by one or more of the following parameters:  

C₂₇H₄₁NO₆S[507]
FAB-MS (neg. Ionen): 506.25 für (M-H)-
UV (MeOH)λmax (log ε) = 210 (4.17); 249 (3.97)C₂₇H₄₁NO₆S [507]
FAB-MS (neg. Ions): 506.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)

IR Film auf Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1 IR film on Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1

DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzt auf 120°C, braune AnfärbungDC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown color

HPLC: Rt = 6,3 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nmHPLC: R t = 6.3 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm

Besonders bevorzugt sind Epothilone mit der folgenden StrukturformelEpothilones with the following structural formula are particularly preferred

worin R₂ Wasserstoff oder Methyl bedeutet. (Das Kohlenstoffatom der Methylgruppe wird als C27 bezeichnet). Ferner betrifft die Erfindung ein Verfahren zum Gewinnen von Epothilonen, insbesondere der vorstehend charakterisierten Epothilone, das dadurch gekennzeichnet ist, daß man den Stamm So ce90 DSM 6773wherein R₂ is hydrogen or methyl. (The carbon atom the methyl group is referred to as C27). Furthermore, the Invention a method for obtaining epothilones, in particular of the epothilones characterized above, which thereby is characterized in that the strain So ce90 DSM 6773

  • - in einem Kohlenstoffquellen, Stickstoffquellen und Mineralsalze enthaltenden Medium kultiviert,- in a carbon sources, nitrogen sources and mineral salts cultivated medium,
  • - entweder während der Kultivierung des Stammes oder anschließend ein Adsorberharz zusetzt,- either during the cultivation of the strain or afterwards adds an adsorber resin,
  • - die Fermenterbrühe abtrennt,- separates the fermenter broth,
  • - die Epothilone aus dem Adsorberharz eluiert und- the epothilones eluted from the adsorber resin and
  • - die Eluate direkt oder über weitere Reinigungsschritte von dem/den Lösungsmittel(n) befreit,- the eluate directly or via further cleaning steps from freed from the solvent (s),
  • - und gegebenenfalls über Hochdruck/Niederdruckchromatographie und/oder Umkristallisation die verschiedenen Epothilone aufreinigt und voneinander trennt.- And if necessary via high pressure / low pressure chromatography and / or recrystallization of the different epothilones purified and separated from each other.

Gegebenenfalls können die so gewonnenen Epothilone mit gängigen chemischen Verfahren weiter umgesetzt werden, z. B. mit Basen in die Alkali- und Erdalkalisalze überführt und gegebenenfalls weiter zu Ethern umgesetzt werden, oder sie können mit organischen Säuren in die entsprechenden Ester überführt werden.If necessary, the epothilones obtained in this way can be used with common chemical processes are further implemented, e.g. B. with bases in the alkali and alkaline earth metal salts are transferred and, if appropriate be further converted to ethers, or they can be organic Acids are converted into the corresponding esters.

Ferner betrifft die Erfindung ein Mittel für den Pflanzenschutz in Landwirtschaft, Forstwirtschaft und/oder Gartenbau, bestehend aus einem oder mehreren der vorstehend aufgeführten Epothilone oder eines oder mehrere dieser Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n). The invention further relates to an agent for crop protection in agriculture, forestry and / or horticulture from one or more of the epothilones listed above or containing one or more of these epothilones, if appropriate in addition to one or more conventional carriers and / or diluents.  

Schließlich betrifft die Erfindung ein therapeutisches Mittel, das insbesondere cytotoxische Aktivitäten entwickeln und/oder Immunsupression bewirken kann, bestehend aus einem oder mehreren der vorstehend aufgeführten Epothilone oder eines oder mehrere dieser Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n).Finally, the invention relates to a therapeutic agent that develop cytotoxic activities in particular and / or Can cause immunosuppression consisting of one or more the epothilones listed above or one or more containing these epothilones, optionally next to one or several common carriers (s) and / or diluent (s).

Im folgenden wird die Erfindung anhand von Beispielen und experimentellen Daten näher erläutert.In the following the invention is illustrated by examples and experimental Data explained in more detail.

ProduktionsstammProduction master

Stamm So ce90 wurde im Juli 1985 an der Gesellschaft für Biotechnologische Forschung (GBF) aus einer Bodenprobe von den Ufern des Zambesi, Südafrika, isoliert. Der Stamm ist bei der Deutschen Sammlung von Mikroorganismen (DSM) unter Nr. 6773 hinterlegt.Strain So ce90 was born in July 1985 at the Society for Biotechnological Research (GBF) a soil sample isolated from the banks of the Zambesi, South Africa. The tribe is with the German Collection of microorganisms (DSM) deposited under No. 6773.

Stammkultur und morphologische Beschreibung: Der Stamm wächst auf Cellulose als einziger Kohlenstoff- und Energiequelle mit KNO₃ als einzige Stickstoffquelle, z. B. auf Filterpapier über ST21 Mineralsalzagar (0.1% KNO₃; 0.1% MgSO₄ × 7 H₂O; 0.1% CaCl₂ × 2 H₂O; 0.1% K₂HPO₄; 0.01% MnSO₄ × 7 H₂O; 0.02% FeCl₃; 0.002% Hefeextrakt; Standard-Spurenelementlösung; 1% Agar). Auf diesem Medium werden dunkelrotbraune bis schwarzbraune Fruchtkörper gebildet, bestehend aus kleinen Sprangiolen (etwa 15 bis 30 µm Durchmesser) in mehr oder weniger großen dichten Haufen und Paketen.Strain culture and morphological description: The stem grows on cellulose as the only carbon and energy source with KNO₃ as the only nitrogen source, for. B. on filter paper over ST21 mineral salt agar (0.1% KNO₃; 0.1% MgSO₄ × 7 H₂O; 0.1% CaCl₂ × 2 H₂O; 0.1% K₂HPO₄; 0.01% MnSO₄ × 7 H₂O; 0.02% FeCl₃; 0.002% yeast extract; standard trace element solution; 1% agar). On this Medium dark red-brown to black-brown fruiting bodies are formed, consisting of small ones Sprangioles (about 15 to 30 µm in diameter) in more or less large dense piles and Packages.

Der Stamm wächst sehr gut mit Glucose und KNO₃, z. B. auf CA2-Agar (Grundmedium: 1.5 g Agar in 92 ml Aqua dest.; Stammlösung 1: 7.5% KNO₃, 7.5% K₂HPO₄ in Aqua dest,; Stammlösung 2: 1.5% MgSO₄ × 7 H₂O in Aqua dest.; Stammlösung 3: 0.2% CaCl₂ × 2 H₂O, 0.15% FeCl₃ in Aqua dest.; Stammlösung 4: 20% Glucose in Aqua dest. Die Stammlösungen werden durch Autoklavieren sterilisiert. Je 1 ml der Lösungen 1 bis 3, sowie 5 ml der Lösung 4 werden dem Grundmedium zugegeben, ebenso eine geeignete Menge einer Spurenelementlösung).The strain grows very well with glucose and KNO₃, e.g. B. on CA2 agar (basic medium: 1.5 g agar in 92 ml aqua dest .; Stock solution 1: 7.5% KNO₃, 7.5% K₂HPO₄ in distilled water ,; Stock solution 2: 1.5% MgSO₄ × 7 H₂O in aqua dest .; Stock solution 3: 0.2% CaCl₂ × 2 H₂O, 0.15% FeCl₃ in distilled water; Stock solution 4: 20% glucose in aqua dest. The stock solutions are made by autoclaving sterilized. 1 ml each of solutions 1 to 3 and 5 ml of solution 4 become the basic medium added, as well as a suitable amount of a trace element solution).

Die vegetativen Stäbchen haben für Sorangium typischen Form (relativ derbe, im Phasenkontrastmikroskop dunkle, zylindrische Stäbchen mit breit abgerundeten Enden, im Mittel 3-6 µm lang und 1 µm dick). Nach längerer Adaptation an das Wachstum in Flüssigmedien wächst der Stamm in homogener Zellsuspension. The vegetative rods have the typical shape of Sorangium (relatively coarse, in a phase contrast microscope dark, cylindrical rods with broadly rounded ends, on average 3-6 µm long and 1 µm thick). After a long adaptation to the growth in liquid media, the strain grows in homogeneous cell suspension.  

Der Stamm So ce90 produziert chemisch nahe verwandte Verbindungen, die antibiotische Aktivität besitzen. Insbesondere sind diese Verbindungen cytotoxisch sowie antifungal wirksam. Hervorzuheben ist z. B. die Hemmung von Mucor hiemlis.The So ce90 strain produces chemically closely related compounds, which have antibiotic activity. In particular are these compounds are cytotoxic and antifungal. To emphasize is z. B. the inhibition of Mucor hiemlis.

Produktion der biologisch aktiven VerbindungenProduction of the biologically active compounds

Die Verbindungen werden während der logarithmischen bis hin zur stationären Wachstumsphase produziert.The connections are made during the logarithmic to the stationary growth phase produced.

Eine typische Fermentation verläuft folgendermaßen: Ein 100 l-Fermenter wird mit 60 l Medium (0.8% Stärke; 0.2% Glucose; 0.2% Soyamehl; 0.2% Hefeextrakt; 0.1% MgSO₄ × 7 H₂O; 8 mg/l Fe-EDTA; pH 7.4) gefüllt. Beimpft wird mit 10 l einer im gleichen Medium jedoch zusäztlich mit 50 mM HEPES-Puffer pH 7.4 in Schüttelkolben angezogenen Vorkultur (160 upm, 30°C). Fermentiert wird bei 32°C mit einer Rührgeschwindigkeit von 500 upm und einer Belüftung von 0.2 NL pro m³ und Std., der pH-Wert wird durch Zugabe von KOH bei 7.4 gehalten. Die Fermentation dauert 7-10 Tage . Die gebildeten aktiven Verbindungen befinden sich teils im Überstand und teils in den Zellen.A typical fermentation proceeds as follows: A 100 l fermenter is mixed with 60 l medium (0.8% Strength; 0.2% glucose; 0.2% soy flour; 0.2% yeast extract; 0.1% MgSO₄ × 7 H₂O; 8 mg / l Fe-EDTA; pH 7.4) filled. Inoculated with 10 l one in the same medium, however, in addition 50 mM HEPES buffer pH 7.4 in pre-culture (160 rpm, 30 ° C) grown in shake flasks. The fermentation takes place at 32 ° C with a stirring speed of 500 rpm and aeration of 0.2  NL per m³ and hour, the pH is kept at 7.4 by adding KOH. The fermentation lasts 7-10 days. The active compounds formed are partly in the supernatant and partly in the cells.

Alternativ dazu kann in Gegenwart von Adsorberharzen (z. B. XAD-1180, Rohm und Haas, 2-5%) fermentiert werden.Alternatively, in the presence of adsorber resins (e.g. XAD-1180, Rohm and Haas, 2-5%) be fermented.

Isolierung von Epothilon A und BIsolation of epothilones A and B

Während der Fermentation von Sorangium cellulosum So ce90 (z. B. 70 l Fermentationsvolumen) in Gegenwart eines Adsorberharzes (z. B.: XAD-1180, Röhm und Haas, 2% v/v) werden die gebildeten Antibiotika Epothilon A (Abb. 1) und B (Abb. 2) vollständig an das Harz gebunden. Nach Abtrennung der Kulturbrühe (z. B. durch Absieben in einem Prozeßfilter) wird das Harz mit 3 Bettvolumen Wasser gewaschen und mit 4 Bettvolumen Methanol eluiert. Die vereinigten Eluate werden im Vakuum bis auf den Wassergehalt eingeengt und dreimal mit je 0,2 l Ethylacetat extrahiert. Die vereinigten Ethylacetatextrakte werden zur Trockne eingeengt (ca. 40 g Trockengewicht).During the fermentation of Sorangium cellulosum So ce90 (e.g. 70 l fermentation volume) in In the presence of an adsorber resin (e.g. XAD-1180, Röhm and Haas, 2% v / v) the formed Antibiotics Epothilon A (Fig. 1) and B (Fig. 2) fully bound to the resin. After separation the culture broth (e.g. by sieving in a process filter) the resin with 3 bed volumes of water washed and eluted with 4 bed volumes of methanol. The combined eluates are vacuumed up to the water content was concentrated and extracted three times with 0.2 l of ethyl acetate. The United Ethyl acetate extracts are evaporated to dryness (approx. 40 g dry weight).

Der Rohextrakt wird in 50 ml Methanol aufgenommen und an Lichroprep RP-18 25-40 µm (Säule: 400 × 100 mm; Fluß: 200 ml/min; Merck Prepbar) isokratisch mit Methanol/Wasser 6/4 chromatographiert. Die Epothilone enthaltenden Fraktionen (Rt ca. 95-125 min) werden durch RP-18 Niederdruckchromatographie aufgereinigt. (Säule 400 × 60; HD-Sil-18-20-60, Labomatic; Laufmittel: Methanol/Wasser 65/35; Fluß 25 ml/min; Rt Epothilon A: 140-165 min; Rt Epothilon B: 170-195 min.The crude extract is taken up in 50 ml of methanol and chromatographed isocratically with methanol / water 6/4 on Lichroprep RP-18 25-40 μm (column: 400 × 100 mm; flow: 200 ml / min; Merck Prepbar). The fractions containing epothilones (R t approx. 95-125 min) are purified by RP-18 low pressure chromatography. (400 × 60 column; HD-Sil-18-20-60, Labomatic; mobile solvent: methanol / water 65/35; flow 25 ml / min; R t epothilone A: 140-165 min; R t epothilone B: 170- 195 min.

Die Feinreinigung der Epothilone erfolgt durch Kristallisation ausThe epothilones are purified by crystallization

  • 1. Epothilon A: Toluol/Ethylacetat = 3 : 21. Epothilon A: toluene / ethyl acetate = 3: 2
  • 2. Epothilon B: Ethylacetat2. Epothilon B: ethyl acetate

Epothilon AEpothilone A

C₂₆H₃₉NO₆S[493]
FAB-MS (neg. Ionen): 429.25 für (M-H)-
¹H-NMR-Daten s. Tab. 1
¹³C-NMR-Daten s. Tab. 2
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion: 1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzen auf 120°C, braune Anfärbung
HPLC: Rt = 5,4 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nmC₂₆H₃₉NO₆S [493]
FAB-MS (neg. Ions): 429.25 for (MH) -
1 H-NMR data s. Tab. 1
13 C NMR data see. Tab. 2
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR film on Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1
DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection: 1. UV quenching at 254 nm
2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ° C, brown color
HPLC: R t = 5.4 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm

Epothilon BEpothilon B

C₂₇H₄₁NO₆S[507]
FAB-MS (neg. Ionen): 506.25 für (M-H)-
¹H-NMR-Daten s. Tab. 1
¹³C-NMR-Daten s. Tab. 2
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzt auf 120°C, braune Anfärbung
HPLC: Rt = 6,3 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nm C₂₇H₄₁NO₆S [507]
FAB-MS (neg. Ions): 506.25 for (MH) -
1 H-NMR data s. Tab. 1
13 C NMR data see. Tab. 2
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR film on Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1
DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown color
HPLC: R t = 6.3 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm

Tabelle 1 Table 1

¹H-NMR-Daten der Epothilone A und B 1 H NMR data of epothilones A and B

Tabelle 2 Table 2

¹³C-NMR-Daten der Epothilone A und B 13 C NMR data of epothilones A and B

Claims (8)

1. Epothilone der allgemeinen Formel: worin R¹ Wasserstoff, C₁-C₄-Alkyl, C₁-C₄-Acyl, Li⁺, K⁺, Na⁺, 1/2 Mg2+ oder 1/2 Ca2+ bedeutet und R² Wasserstoff oder eine Methylgruppe darstellt.1. Epothilones of the general formula: wherein R¹ is hydrogen, C₁-C₄-alkyl, C₁-C₄-acyl, Li⁺, K⁺, Na⁺, 1/2 Mg 2+ or 1/2 Ca 2+ and R² represents hydrogen or a methyl group. 2. Epothilone der allgemeinen Formel: worin R² Wasserstoff oder Methyl ist.2. Epothilones of the general formula: wherein R² is hydrogen or methyl. 3. Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: C₂₆H₃₉NO₆S[493]
FAB-MS (neg. Ionen): 492.25 für (M-H)-
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)IR Film auf Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzen auf 120°C, braune AnfärbungHPLC: Rt = 5,4 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nm3. epothilone, characterized by one or more of the following parameters: C₂₆H₃₉NO₆S [493]
FAB-MS (neg. Ions): 492.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97) IR film on Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1
DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown staining HPLC: R t = 5.4 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm 4. Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: C₂₇H₄₁NO₆S[507]
FAB-MS (neg. Ionen): 506.25 für (M-H)-
UV (MeOH)λmax (log ε) = 210 (4.17); 249 (3.97)IR Film auf Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanilin/Schwefelsäure-Reagenz und erhitzt auf 120°C, braune AnfärbungHPLC: Rt = 6,3 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nm4. epothilone, characterized by one or more of the following parameters: C₂₇H₄₁NO₆S [507]
FAB-MS (neg. Ions): 506.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97) IR film on Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1 DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanilin / sulfuric acid reagent and heat to 120 ° C, brown staining HPLC: R t = 6.3 min
Column: 4 × 250 mm Lichrosorb RP-18 7 µm, Merck;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm 5. Verfahren zum Herstellen von Epothilonen nach einem der voranstehenden Ansprüche , dadurch gekennzeichnet, daß man den Stamm So ce90
  • - in einem Kohlenstoffquellen, Stickstoffquellen und Mineralsalze enthaltenden Medium kultiviert,
  • - entweder während der Kultivierung des Stammes oder anschließend ein Adsorberharz zusetzt,
  • - die Fermenterbrühe abtrennt,
  • - die Epothilone aus dem Adsorberharz eluiert und
  • - die Eluate direkt oder über weitere Reinigungsschritte von dem/den Lösungsmittel(n) befreit,
  • - und gegebenenfalls über Hochdruck/Niederdruckchromatographie und/oder Umkristallisation die verschiedenen Epothilone aufreinigt und voneinander trennt.
5. Process for the preparation of epothilones according to one of the preceding claims, characterized in that the strain So ce90
  • - cultivated in a medium containing carbon sources, nitrogen sources and mineral salts,
  • - either during the cultivation of the strain or subsequently adding an adsorber resin,
  • - separates the fermenter broth,
  • - the epothilones eluted from the adsorber resin and
  • - the eluates are freed from the solvent (s) directly or through further cleaning steps,
  • - and, if necessary, the various epothilones are purified and separated from one another by means of high pressure / low pressure chromatography and / or recrystallization.
6. Mittel für den Pflanzenschutz in der Landwirtschaft und Forstwirtschaft und/oder im Gartenbau, bestehend aus einem oder mehreren Epothilonen gemäß einem der voranstehenden Ansprüche oder eines oder mehrerer dieser Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n).6. Means for plant protection in agriculture and Forestry and / or horticulture, consisting of one or several epothilones according to one of the preceding claims or containing one or more of these epothilones, if appropriate in addition to one or more conventional carriers and / or Diluent (s). 7. Mittel nach Anspruch 6, dadurch gekennzeichnet, daß es ein Fungizid oder Fungistatikum ist.7. Composition according to claim 6, characterized in that it is a Is a fungicide or fungistatic. 8. Therapeutisches Mittel, das insbesondere cytotoxische Aktivitäten entwickeln und/oder Immunsuppresion bewirken kann, bestehend aus einem oder mehreren Epothilonen nach einem der Ansprüche 1 bis 4 oder diese Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n).8. Therapeutic agent, especially cytotoxic activities develop and / or cause immunosuppression, consisting from one or more epothilones according to one of the claims 1 to 4 or containing these epothilones, if appropriate in addition to one or more conventional carriers and / or diluents.
DE19914138042 1991-11-19 1991-11-19 Epothilones, their production processes and agents containing these compounds Expired - Lifetime DE4138042C2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE19914138042 DE4138042C2 (en) 1991-11-19 1991-11-19 Epothilones, their production processes and agents containing these compounds
AU29437/92A AU2943792A (en) 1991-11-19 1992-11-19 Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents
PCT/EP1992/002656 WO1993010121A1 (en) 1991-11-19 1992-11-19 Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19914138042 DE4138042C2 (en) 1991-11-19 1991-11-19 Epothilones, their production processes and agents containing these compounds

Publications (2)

Publication Number Publication Date
DE4138042A1 true DE4138042A1 (en) 1993-05-27
DE4138042C2 DE4138042C2 (en) 1993-10-14

Family

ID=6445140

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19914138042 Expired - Lifetime DE4138042C2 (en) 1991-11-19 1991-11-19 Epothilones, their production processes and agents containing these compounds

Country Status (3)

Country Link
AU (1) AU2943792A (en)
DE (1) DE4138042C2 (en)
WO (1) WO1993010121A1 (en)

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636343C1 (en) * 1996-08-30 1997-10-23 Schering Ag New (di:methyl)-dioxanyl-methyl-pentanone and related compounds
WO1998022461A1 (en) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
WO1998038192A1 (en) * 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilones with a modified side chain
WO1999007692A2 (en) * 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
EP1019389A2 (en) * 1997-07-08 2000-07-19 Bristol-Myers Squibb Company Epothilone derivatives
EP1073647A1 (en) * 1998-04-21 2001-02-07 Bristol-Myers Squibb Company 12,13-cyclopropane epothilone derivatives
EP1073654A1 (en) * 1998-04-21 2001-02-07 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6288237B1 (en) 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6531497B1 (en) 1998-06-22 2003-03-11 The Scripps Research Institute Epothilone derivatives and their synthesis and use
US6576651B2 (en) 2001-01-25 2003-06-10 Bristol-Myers Squibb Company Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6670384B2 (en) 2001-01-25 2003-12-30 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6686380B2 (en) 2001-02-20 2004-02-03 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
US6689802B2 (en) 2000-08-16 2004-02-10 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
US6727276B2 (en) 2001-02-20 2004-04-27 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
WO2004085388A2 (en) 2003-03-24 2004-10-07 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6900160B2 (en) 2000-09-22 2005-05-31 Gesellschaft Fuer Biotechnologische Forschung Mbh Triazolo-epothilones
WO2005051947A1 (en) * 2003-11-26 2005-06-09 Leibniz-Institut Für Pflanzenbiochemie (Ipb) Thiaepothilone for treating cancerous diseases
US6936628B2 (en) 2002-04-04 2005-08-30 Bristol-Myers Squibb Company Oral administration of epothilones
WO2005084295A2 (en) 2004-03-01 2005-09-15 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
US7001916B1 (en) 1999-02-11 2006-02-21 Schering, Ag Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7022330B2 (en) 2001-01-25 2006-04-04 Bristol-Myers Squibb Company Parenteral formulation for epothilone analogs
US7053069B2 (en) 2002-05-15 2006-05-30 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7091226B2 (en) 1998-02-25 2006-08-15 Novartis Ag Cancer treatment with epothilones
US7125893B1 (en) 1999-04-30 2006-10-24 Schering Ag 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US7173137B2 (en) * 1996-12-13 2007-02-06 The Scripps Research Institute Epothilone analogs
US7172884B2 (en) 2002-09-23 2007-02-06 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7759374B2 (en) 2002-08-23 2010-07-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
US7875638B2 (en) 2002-08-23 2011-01-25 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP2308833A2 (en) 1999-04-15 2011-04-13 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US8017749B2 (en) 2006-12-04 2011-09-13 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
WO2013041014A1 (en) 2011-09-19 2013-03-28 北京市丰硕维康技术开发有限责任公司 Platinum compound having amino- or alkylamino-containing succinic acid derivatives as leaving group, preparation method therefor, and use thereof
WO2014075391A1 (en) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
US8871227B2 (en) 2003-11-04 2014-10-28 Bristol-Myers Squibb Company Process and formulation containing epothilones and analogs thereof
US9138421B2 (en) 2011-07-09 2015-09-22 Beijing Fswelcome Technology Development Co., Ltd. Platinum compounds for treating cell proliferative diseases, preparation method and use thereof

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
AU716610B2 (en) * 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE69734362T2 (en) * 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research SYNTHESIS OF EPOTHILONES, INTERMEDIATE PRODUCTS, ANALOGUES AND USES THEREOF
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
HUP0100582A3 (en) * 1997-12-04 2003-03-28 Bristol Myers Squibb Co A process for the reduction of oxiranyl epothilones to olefinic epothilones
CA2320182C (en) * 1998-02-05 2008-11-25 Novartis Ag Compositions containing organic compounds
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
DE19820599A1 (en) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh New epothilone derivatives useful as pharmaceuticals and in plant protection
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
ES2175575T3 (en) * 1998-08-05 2002-11-16 Biotechnolog Forschung Gmbh PHARMACEUTICAL AGENTS CONTAINING EPOTILONE N-OXIDE A AND / OR N-OXIDODE EPOTILONE B.
DE19848306A1 (en) * 1998-10-14 2000-04-20 Schering Ag High yield preparation of cytotoxic or fungicidal compound epothilon B, from phenylsulfonyl-butanol derivative by multistage process via new thiazole derivative intermediates
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
GB0003753D0 (en) * 2000-02-17 2000-04-05 Biochemie Gmbh Organic compounds
US20020077290A1 (en) 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
GB0029895D0 (en) * 2000-12-07 2001-01-24 Novartis Ag Organic compounds
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
CN1511036B (en) 2001-02-27 2010-05-05 诺瓦提斯公司 Combination comprising signal transduction inhibitor and epothilone derivative
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US6884608B2 (en) 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
AU2003235761A1 (en) 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
AU2003218110A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
DE10344882A1 (en) 2003-09-26 2005-04-21 Morphochem Ag Komb Chemie New macrocycles for the treatment of cancer
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CN1312286C (en) * 2005-10-19 2007-04-25 华南理工大学 Method for highly-effective producing epothilone using myxobacteria sorangium cellulosum
EP1994412A2 (en) 2006-03-31 2008-11-26 Brystol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US8143415B2 (en) 2007-05-25 2012-03-27 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
DE102007059752A1 (en) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Functionalized solid polymer nanoparticles containing epothilones
EP2241566B1 (en) * 2008-02-01 2013-08-21 Zhejiang Hisun Pharmaceutical Co. Ltd. A method for the separation and purification of epothilones
CN101362784A (en) * 2008-10-06 2009-02-11 山东大学 Ebomycin glycosides compounds, composition using the same as activity component and use thereof
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
US8618146B2 (en) 2011-01-03 2013-12-31 Dr. Reddy's Laboratories Limited Epothilone compound formulations
CN103145722B (en) * 2013-03-05 2015-12-02 福建省微生物研究所 A kind of method of high speed adverse current chromatogram separating-purifying ebormycine
EP3036240A1 (en) * 2013-08-19 2016-06-29 Sandoz AG Method for the purifiction of epothilones via crystallization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICHTS ERMITTELT *

Cited By (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288237B1 (en) 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6831076B2 (en) 1995-11-17 2004-12-14 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
US6613912B2 (en) 1995-11-17 2003-09-02 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
DE19636343C1 (en) * 1996-08-30 1997-10-23 Schering Ag New (di:methyl)-dioxanyl-methyl-pentanone and related compounds
WO1998022461A1 (en) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
US7846952B2 (en) 1996-11-18 2010-12-07 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilones C, D, E, and F, preparation and compositions
US8076490B2 (en) 1996-11-18 2011-12-13 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilones C, D, E, and F, preparation and compositions
EP1367057A1 (en) * 1996-11-18 2003-12-03 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilones C, E and F
US7173137B2 (en) * 1996-12-13 2007-02-06 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
WO1998038192A1 (en) * 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilones with a modified side chain
USRE41895E1 (en) 1997-07-08 2010-10-26 Bristol-Myers Squibb Company Epothilone derivatives
CZ297904B6 (en) * 1997-07-08 2007-04-25 Bristol-Myers Squibb Company Epothilone derivatives
EP1526133A1 (en) * 1997-07-08 2005-04-27 Bristol-Myers Squibb Company Epothilone derivatives
EP1531153A1 (en) * 1997-07-08 2005-05-18 Bristol-Myers Squibb Company Epothilone derivatives
US7241755B2 (en) 1997-07-08 2007-07-10 Bristol-Myers Squibb Company Epothilone derivatives
EP1019389A4 (en) * 1997-07-08 2001-11-07 Bristol Myers Squibb Co Epothilone derivatives
US8536327B2 (en) 1997-07-08 2013-09-17 Bristol-Myers Squibb Company Epothilone derivatives
US8921542B2 (en) 1997-07-08 2014-12-30 Bristol-Myers Squibb Company Epothilone derivatives
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP1493738A1 (en) * 1997-07-08 2005-01-05 Bristol-Myers Squibb Company Epothilone derivatives
USRE41911E1 (en) 1997-07-08 2010-11-02 Bristol-Myers Squibb Company Epothilone derivatives
US7125899B2 (en) 1997-07-08 2006-10-24 Bristol-Myers Squibb Company Epothilone derivatives
USRE43003E1 (en) 1997-07-08 2011-12-06 Bristol-Myers Squibb Company Epothilone derivatives
EP1019389A2 (en) * 1997-07-08 2000-07-19 Bristol-Myers Squibb Company Epothilone derivatives
USRE41893E1 (en) 1997-07-08 2010-10-26 Bristol-Myers Squibb Company Epothilone derivatives
WO1999007692A3 (en) * 1997-08-09 1999-05-14 Schering Ag New epothilone derivatives, method for producing same and their pharmaceutical use
WO1999007692A2 (en) * 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
EP1847540A1 (en) * 1997-08-09 2007-10-24 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés d'épothilone, leur procédé de production et leur utilisation pharmaceutique
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US7101702B2 (en) 1998-02-19 2006-09-05 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6380227B1 (en) 1998-02-19 2002-04-30 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6656711B2 (en) 1998-02-19 2003-12-02 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US7091226B2 (en) 1998-02-25 2006-08-15 Novartis Ag Cancer treatment with epothilones
US7875601B2 (en) 1998-02-25 2011-01-25 Novartis Ag Cancer treatment with epothilones
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
EP1589017A3 (en) * 1998-04-21 2009-04-22 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
EP1073647A1 (en) * 1998-04-21 2001-02-07 Bristol-Myers Squibb Company 12,13-cyclopropane epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
EP1073648A1 (en) * 1998-04-21 2001-02-07 Bristol-Myers Squibb Company 12,13-Modified epothilone derivatives
EP1073654A4 (en) * 1998-04-21 2003-01-02 Bristol Myers Squibb Co 2,3-olefinic epothilone derivatives
EP1073647A4 (en) * 1998-04-21 2003-01-02 Bristol Myers Squibb Co 12,13-cyclopropane epothilone derivatives
US6831090B2 (en) 1998-04-21 2004-12-14 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
EP1073654A1 (en) * 1998-04-21 2001-02-07 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
EP1073648A4 (en) * 1998-04-21 2003-01-02 Bristol Myers Squibb Co 12,13-modified epothilone derivatives
US7579366B2 (en) 1998-06-22 2009-08-25 The Scripps Research Institute Epothilone derivatives and their synthesis and use
US6531497B1 (en) 1998-06-22 2003-03-11 The Scripps Research Institute Epothilone derivatives and their synthesis and use
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
US6583290B1 (en) 1998-11-20 2003-06-24 Kosam Biosciences, Inc. 14-methyl epothilone derivatives
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US7402421B2 (en) 1998-11-20 2008-07-22 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US7732186B2 (en) 1998-11-20 2010-06-08 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6921650B1 (en) 1998-11-20 2005-07-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US7129071B1 (en) 1998-11-20 2006-10-31 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6858411B1 (en) 1998-11-20 2005-02-22 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US7067286B2 (en) 1998-11-20 2006-06-27 Kosan Biosciences, Inc. Cystobacterineae host cells containing heterologous PKS genes for the synthesis of polykedtides
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US7244594B2 (en) 1998-12-23 2007-07-17 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US7001916B1 (en) 1999-02-11 2006-02-21 Schering, Ag Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
US6262094B1 (en) 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
EP3222619A1 (en) 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
EP2308833A2 (en) 1999-04-15 2011-04-13 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125893B1 (en) 1999-04-30 2006-10-24 Schering Ag 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US7700621B2 (en) 1999-04-30 2010-04-20 Bayer Schering Pharma Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
USRE39356E1 (en) * 2000-03-20 2006-10-17 Bristol-Myers Squibb Co. Process for the preparation of epothilone analogs
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US7153879B2 (en) 2000-08-16 2006-12-26 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
USRE39251E1 (en) * 2000-08-16 2006-08-29 Bristol-Myers Squibb Co. Polymorphs of an epothilone analog
US6982276B2 (en) 2000-08-16 2006-01-03 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
US6689802B2 (en) 2000-08-16 2004-02-10 Bristol-Myers Squibb Company Polymorphs of an epothilone analog
US6900160B2 (en) 2000-09-22 2005-05-31 Gesellschaft Fuer Biotechnologische Forschung Mbh Triazolo-epothilones
US7022330B2 (en) 2001-01-25 2006-04-04 Bristol-Myers Squibb Company Parenteral formulation for epothilone analogs
US8632788B2 (en) 2001-01-25 2014-01-21 Bristol-Myers Squibb Company Parenteral formulation for epothilone analogs
US6576651B2 (en) 2001-01-25 2003-06-10 Bristol-Myers Squibb Company Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
USRE40387E1 (en) * 2001-01-25 2008-06-17 Bristol-Myers Squibb Company Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones
US6670384B2 (en) 2001-01-25 2003-12-30 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
USRE41393E1 (en) 2001-02-20 2010-06-22 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
US6686380B2 (en) 2001-02-20 2004-02-03 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
US6727276B2 (en) 2001-02-20 2004-04-27 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
US8598215B2 (en) 2001-03-14 2013-12-03 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US8569347B2 (en) 2001-03-14 2013-10-29 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
US6936628B2 (en) 2002-04-04 2005-08-30 Bristol-Myers Squibb Company Oral administration of epothilones
US7053069B2 (en) 2002-05-15 2006-05-30 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7759374B2 (en) 2002-08-23 2010-07-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US8110590B2 (en) 2002-08-23 2012-02-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7875638B2 (en) 2002-08-23 2011-01-25 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8513429B2 (en) 2002-08-23 2013-08-20 Sloan-Kettering Insitute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7241899B2 (en) 2002-09-23 2007-07-10 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
USRE42191E1 (en) 2002-09-23 2011-03-01 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
US7172884B2 (en) 2002-09-23 2007-02-06 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B
US7767432B2 (en) 2002-09-23 2010-08-03 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
WO2004085388A2 (en) 2003-03-24 2004-10-07 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US8871227B2 (en) 2003-11-04 2014-10-28 Bristol-Myers Squibb Company Process and formulation containing epothilones and analogs thereof
WO2005051947A1 (en) * 2003-11-26 2005-06-09 Leibniz-Institut Für Pflanzenbiochemie (Ipb) Thiaepothilone for treating cancerous diseases
US7381743B2 (en) 2003-11-26 2008-06-03 Leibniz-Institut Fuer Pflanzenbiochemie (Ipb) Macrocycles for the treatment of cancer
WO2005084295A2 (en) 2004-03-01 2005-09-15 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17b-hydroxysteroid dehydrogenase 3
US8017749B2 (en) 2006-12-04 2011-09-13 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
US9969781B2 (en) 2006-12-04 2018-05-15 Tapas Das Gupta Compositions and methods to treat cancer with CpG rich DNA and cupredoxins
US11046733B2 (en) 2006-12-04 2021-06-29 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with CpG rich DNA and cupredoxins
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
US9138421B2 (en) 2011-07-09 2015-09-22 Beijing Fswelcome Technology Development Co., Ltd. Platinum compounds for treating cell proliferative diseases, preparation method and use thereof
US9175024B2 (en) 2011-09-19 2015-11-03 Beijing Fswelcome Technology Development Co., Ltd. Platinum compound having amino or alkylamino-containing succinic acid derivatives as leaving group, preparation method thereof, and use thereof
WO2013041014A1 (en) 2011-09-19 2013-03-28 北京市丰硕维康技术开发有限责任公司 Platinum compound having amino- or alkylamino-containing succinic acid derivatives as leaving group, preparation method therefor, and use thereof
WO2014075391A1 (en) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
US9725477B2 (en) 2012-11-17 2017-08-08 Beijing Fswelcome Technology Development Co., Ltd Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino

Also Published As

Publication number Publication date
WO1993010121A1 (en) 1993-05-27
DE4138042C2 (en) 1993-10-14
AU2943792A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
DE4138042C2 (en) Epothilones, their production processes and agents containing these compounds
EP1367057B1 (en) Epothilones E and F
WO1998013375A1 (en) Compounds with antimycotic and cytostatic effect, preparation method, agent containing these compounds and dsm 11 092
KR960012212B1 (en) Herbicide, its preparation and use
EP0282455A2 (en) Method for the preparation of a macrocyclic compound
EP0342363A2 (en) Angucyclinones from streptomyces, process to obtain them and their use
EP0337152A1 (en) Furans and lactones from streptomycetes, process for their preparation and their use
DD202047A5 (en) PROCESS FOR PREPARING THE MAKROLIDE 20-DIHYDRO-20,23-DIDEOXYTYLONOLIDE
DE2921085C2 (en)
PL163447B1 (en) Microbiological method form manufacturingmacrocyclic compounds
DE4211056C1 (en) Spiran heterocyclic deriv. for controlling fungi and bacteria uncontrollable - prepd. by fermenting Sorangium e.g. Polyangium cellulosum in medium contg. carbon and nitrogen sources and mineral salts in adsorber resin, and eluting
DE3823067A1 (en) Chemical compound with antibiotic activity and preparation process
DE19630980B4 (en) Etnangien, production, use and production strain sorangium cellulosum DSM 11 028
EP1373245B1 (en) Intermediates for producing spinosyns
US5397570A (en) Antibiotics AB-023 and process for preparing them
EP0339442A2 (en) Angucyclinones from streptomyces, process to obtain them and their use
DE3922283C1 (en)
DE19636721A1 (en) Antibiotic and antitumor compound, manufacturing process, agent and DSM 11 071
DE3707955C1 (en) Chemical compounds of the molecular formulae C29H44O8 and C28H44O8, process for their preparation and compositions containing them
DE3840519A1 (en) NEW ANGUCYCLINONE FROM STREPTOMYCETES, PROCESS FOR THEIR PREPARATION AND THEIR USE
DE19607702A1 (en) Heterocyclic compounds, manufacturing processes and agents
DE2921052C2 (en)
DE2659180C2 (en) Antibiotic derivative of the substance SF-1540 and process for its preparation
DE4305486A1 (en) Icumazoles and preparation processes
AT329760B (en) PROCESS FOR THE PREPARATION OF DEACETOXYCEPHALOSPORIN C

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
R071 Expiry of right